Skip to main content
Premium Trial:

Request an Annual Quote

Inivata to Test Liquid Biopsy Against Tissue Sequencing in French Prospective Clinical Trial

NEW YORK – Liquid biopsy firm Inivata said today that it is launching a prospective clinical study with France's Centre Léon Bérard cancer center to test whether its InVisionFirst-Lung test can get patients on appropriate treatment more quickly than tissue-based genetic testing.

The randomized Phase III interventional trial is called LIquid Biopsy for the Early detection of LUng cancer LEsion (LIBELULE). Investigators plan to enroll at least 286 patients across 17 clinical sites in France.

The primary endpoint — a reduction in time to treatment of more than 20 percent overall, or up to 50 percent for specific molecular subgroups — was chosen to answer the question of whether liquid biopsy assays like Inivata's can, or should, be used in routine clinical practice. However, investigators will also be measuring clinical outcomes, including progression-free survival.

Inivata has made a point to push for definitive evidence for the non-inferiority of its liquid biopsy approach over the last several years.

"We are committed to continuing to build a highly robust body of evidence around the use of our liquid biopsy tests … and are proud to be working with high-quality teams around the world to develop a deeper understanding of the impact InVisionFirst-Lung can have on treatment," Inivata CEO Clive Morris said in a statement.

Various other liquid biopsy companies have also hit on the question of timely treatment decisions as a way to promote and advance their assays, with some, like Guardant Health, promoting a "blood first paradigm," in which liquid biopsy tests are ordered first and tissue sequencing becomes more of a backup or reflex for those with negative blood-based results.

Inivata's new study with Centre Léon Bérard will be the first of its kind to prospectively enroll and randomly stratify patients for therapeutic intervention based solely on a liquid biopsy result versus a tissue test.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.